The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Perioperative genotype-dosed FOLFIRINOX with margin-negative resection in gastroesophageal cancer

Name: Perioperative genotype-dosed FOLFIRINOX with margin-negative resection in gastroesophageal cancer
Uploaded: 2020-07-06T00:00:00Z
Duration: 5 min 59 s
Description: Daniel Catenacci, MD, University of Chicago, Chicago, IL, outlines pharmacogenomically dosed perioperative FOLFIRINOX in patients with locally advanced gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Daniel Catenacci • 6 Jul 2020

ESMO WCGIC 2020

Gastroesophageal Cancer Gastrointestinal Cancer Cisplatin Epirubicin Folfirinox Irinotecan Oxaliplatin

MAGIC

Daniel Catenacci, MD, University of Chicago, Chicago, IL, outlines pharmacogenomically dosed perioperative FOLFIRINOX in patients with locally advanced gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).